Cancer Causes & Control

, Volume 23, Issue 10, pp 1739–1744

Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas

Authors

    • Chao Family Comprehensive Cancer CenterUniversity of California
    • Division of Hematology/Oncology, Department of MedicineUniversity of California
    • Department of EpidemiologyUniversity of California
    • Division of Hematology/OncologyUniversity of California Irvine Medical Center
  • Bruce S. Lin
    • Chao Family Comprehensive Cancer CenterUniversity of California
    • Division of Hematology/Oncology, Department of MedicineUniversity of California
    • Department of EpidemiologyUniversity of California
  • Nikki Madson
    • Department of EpidemiologyUniversity of California
    • Division of Human Genetics and Metabolism, Department of PediatricsUniversity of California
  • Christine E. McLaren
    • Chao Family Comprehensive Cancer CenterUniversity of California
    • Department of EpidemiologyUniversity of California
  • Eugene W. Gerner
    • Department of Cell Biology and AnatomyCollege of Medicine
    • Gastrointestinal Cancer ProgramArizona Cancer Center
  • Frank L. Meyskens
    • Chao Family Comprehensive Cancer CenterUniversity of California
    • Division of Hematology/Oncology, Department of MedicineUniversity of California
    • Department of Biological SciencesUniversity of California
Open AccessBrief report

DOI: 10.1007/s10552-012-0051-6

Cite this article as:
Zell, J.A., Lin, B.S., Madson, N. et al. Cancer Causes Control (2012) 23: 1739. doi:10.1007/s10552-012-0051-6

Abstract

Background

Chemoprevention with the polyamine-inhibitory regimen difluoromethylornithine (DFMO) + sulindac markedly reduces risk of recurrent adenoma in colorectal adenoma patients. Obesity is associated with risk of colorectal adenoma and colorectal cancer. This study investigates how obesity influences risk of recurrent adenoma after prolonged treatment with DFMO + sulindac versus placebo.

Methods

Our analysis included subjects enrolled in the phase III colorectal adenoma prevention clinical trial investigating DFMO + sulindac versus placebo. Patients were classified by obesity (body mass index, BMI ≥ 30 kg/m2) status at baseline. Pearson χ2 statistic and Mann–Whitney U test were used to compare baseline characteristics, including rectal tissue polyamine levels. Log-binomial regression analysis was used to determine the risk ratio (RR) of recurrent adenomas, adjusted for covariates and an interaction term for obesity and treatment.

Results

The final analytic cohort was comprised of 267 patients. In separate regression models, the risk of adenoma recurrence after treatment compared to placebo was similar for obese (RR = 0.32, 95 % CI 15–71) and non-obese patients (RR = 0.27, 95 % CI 15–49). No significant interaction was detected between obesity, treatment, and risk of colorectal adenoma in the full regression model (p interaction = 0.91).

Conclusions

Obesity does not substantially modify the colorectal adenoma risk reduction ascribed to DFMO + sulindac versus placebo.

Keywords

Body mass index BMI Colorectal adenoma Chemoprevention Difluoromethylornithine Obesity Sulindac

Introduction

Polyamines are naturally occurring substances that, in excess, are associated with colorectal carcinogenesis in animal models [1]. In a randomized phase III trial of colorectal adenoma (CRA) patients, the risk of CRA recurrence was decreased by 70 % after 3 years of treatment with the polyamine-inhibitory regimen difluoromethylornithine (DFMO) + sulindac compared to placebo. These effects were shown to occur via polyamine-dependent processes [2], with differential treatment outcomes based on genetic polymorphism of ODC1 (ornithine decarboxylase-1)—a key regulatory gene of polyamine metabolism [3]. Numerous observational studies have reported associations between obesity and risk of CRA or colorectal cancer (CRC), with variable reporting of obesity-associated risks based on gender, colorectal subsite, and adenoma characteristics (e.g., number, size, histology, and high-risk features) [49]. Polyamine metabolism and its inhibition have been associated with increased adipose tissue and weight gain in animal models. Murine experiments reveal that polyamine inhibition via knockout of spermidine spermine acetyltransferase, SSAT (a gene encoding SSAT, which is responsible for polyamine acetylation and subsequent cellular polyamine export), results in deceased fatty acid catabolism, increased tissue adipose content, and increased weight gain [10]. These findings indicate potential links between obesity and polyamine inhibition in humans. Polyamines are derived from dietary sources in humans (meats, corn, peas, grapefruit juice) [11]. However, potential relationships between energy balance and polyamine-related colorectal carcinogenesis have not been described in humans. Here, we examine whether obesity modifies the adenoma risk reduction conferred by polyamine-inhibitory treatment among colorectal adenoma patients.

Materials and methods

The parent study was a randomized, double-blind, placebo-controlled multi-site clinical trial to determine the effect of DFMO + sulindac on CRA recurrence [12]. Eligible patients were between 40 and 80 years of age with a history of ≥1 resected adenoma (≥3 mm) within 5 years before study entry. All patients underwent colonoscopy and removal of any preexisting polyps within 6 months of study entry. Body mass index (BMI) was calculated with direct measurement of each participant’s height and weight. The proportion of obese (BMI ≥ 30 kg/m2) versus non-obese (BMI < 30 kg/m2) patients was similar between screened (34 % vs. 66 %), enrolled (33 % vs. 67 %), and non-enrolled participants (40 % vs. 60 %). The study was approved by the University of California-Irvine Institutional Review Board (# 2002–2261).

In the parent trial, a total of 375 subjects were randomized; planned treatment duration was 36 months. At the second interim analysis, the study was halted by the Data Safety and Monitoring Board since clinical efficacy endpoints were achieved. For the present analysis, data were obtained from all 267 patients completing end-of-study colonoscopies. The primary objective of the present study was to determine whether obesity modifies the effect of DFMO + sulindac (vs. placebo) on CRA recurrence. Two categories were defined by BMI status including a non-obese and obese group. For the comparisons of baseline characteristics of patients in the obese versus non-obese groups, dichotomous variables were created to represent factors previously associated with increased risk of advanced metachronous adenoma. These included the presence of proximal (right-sided) lesions, defined as those in the transverse colon, right colon, and cecum; large adenomas, defined as ≥10 mm in size; multiple adenomas (3 or more); adenomas with advanced histology (i.e., villous or tubulovillous features, high-grade dysplasia, and carcinoma-in situ); and high-risk lesions, which included either advanced adenomas, multiple adenomas, or those >10 mm in size.

Statistical analysis

Comparisons of demographic, clinical, and pathological variables were performed using Pearson χ2 statistic for nominal variables and Mann–Whitney U test for continuous variables that were not normally distributed: age, tissue polyamines, and number of adenomas. The risk ratio of development of any recurrent adenoma was assessed by log-binomial regression, with adjustment for treatment group, obesity, age, aspirin use, and a term representing the interaction of obesity and treatment group. Aspirin use was included in the model as this was a stratification factor in the parent trial and used in the primary efficacy analyses of that trial [12]. Age was included in the full regression model (containing obese and non-obese patients) due to the baseline differences observed in the obese versus non-obese groups and excluded from the multivariate regression models that were restricted to either the obese group or non-obese group. Seventy-two patients had developed metachronous adenomas in the final dataset. Statistical analyses were conducted using SAS 9.2 statistical software (SAS Inc., Cary, NC).

Results

Baseline characteristics of the final analytic cohort are presented in Table 1. The median age of all participants was 60.8 years. The median BMI was 28.8 kg/m2, with a range of 17.0–52.4 kg/m2. The non-obese group consisted of approximately twice as many patients as the obese group. The obese group was significantly younger than the non-obese group: 59.0 versus 61.9 years (p = 0.004). No significant differences were observed between obesity groups for gender, ethnicity, aspirin use, treatment received, or baseline rectal tissue polyamine contents. Significant baseline differences in adenoma characteristics between obese and non-obese patients were observed.
Table 1

Clinicopathologic baseline characteristics of the final analytic cohort

 

All (n = 267)

BMI < 30 (n = 181)

BMI ≥ 30 (n = 86)

p*

Age (years)

Median

60.8

61.9

59.0

0.004a

Range

41.4–78.8

41.4–78.8

42.4–73.8

Sex

Male

202 (75.7 %)

138 (76.2 %)

64 (74.4 %)

0.74

Female

65 (24.3 %)

43 (23.8 %)

22 (25.6 %)

 

Ethnicity

Asian/Pacific Islander

12 (4.5 %)

11 (6.1 %)

1 (1.1 %)

0.14

Black

8 (3.0 %)

5 (2.8 %)

3 (3.5 %)

Hispanic

19 (7.1 %)

9 (5.0 %)

10 (11.6 %)

White

224 (83.9 %)

153 (84.5 %)

71 (82.6 %)

Other

4 (1.5 %)

3 (1.7 %)

1 (1.1 %)

Aspirin use

Yes

103 (38.6 %)

74 (40.9 %)

29 (33.7 %)

0.26

No

164 (61.4 %)

107 (59.1 %)

57 (66.3 %)

BMI (kg/m 2 )

Median

28.8

Range

17.0–52.4

95 % CI

21.9–39.3

Treatment

DFMO/sulindac

138 (51.7 %)

95 (52.5 %)

43 (50.0 %)

0.70

Placebo

129 (49.3 %)

86 (47.5 %)

43 (50.0 %)

Tissue polyamines b (nmol/mg) c

Putrescine

 Median

0.49

0.5

0.49

0.58a

 Range

0.01–5.29

0.01–5.29

0.01–3.27

Spermidine

 Median

2.06

2.07

2.05

0.93a

 Range

0.76–11.45

0.76–9.18

1.05–11.45

Spermine

 Median

7.07

7.07

7.12

0.43a

 Range

2.29–34.10

2.29–28.31

3.88–34.10

Spermidine:spermine Ratio

 Median

0.3

0.3

0.29

0.33a

 Range

0.19–0.98

0.19–0.98

0.20–0.76

Number of adenomas b

Mean

2.4 (± 2.0 SD)

2.2 (± 1.6 SD)

3.0 (± 2.6 SD)

0.006

Median

2

2

2

95 % CI

1–6

1–6

1–8

Adenoma size (mm)

<10

183 (68.5 %)

136 (75.1 %)

47 (54.6 %)

0.0008

≥10

84 (31.5 %)

45 (24.9 %)

39 (45.4 %)

Multiple adenomas b

<3

182 (68.9 %)

132 (73.7 %)

50 (58.8 %)

0.01

≥3

82 (31.1 %)

47 (26.3 %)

35 (41.2 %)

Advanced adenoma histology d

Yes

46 (17.2 %)

24 (13.3 %)

22 (25.6 %)

0.013

No

221 (82.8 %)

157 (86.7 %)

64 (74.4 %)

Location e

Proximalf

99 (37.2 %)

78 (43.3 %)

21 (24.4 %)

0.003

Distalg

167 (62.8 %)

102 (56.7 %)

65 (75.6 %)

High-risk adenomas h

Yes

144 (53.9 %)

82 (45.3 %)

62 (72.1 %)

<0.0001

No

123 (46.1 %)

99 (54.7 %)

24 (27.9 %)

* p values indicate comparisons between the obese and non-obese groups

aMann–Whitney U test

bData missing from three patients

cnmol polyamine per milligram protein

dIncludes adenomas with villous or tubulovillous features, high-grade dysplasia, or carcinoma-in situ

eData missing from one patient

fIncludes the cecum, right colon, and transverse colon

gIncludes the left colon and rectum

hIncludes adenomas >1 cm in size, multiple adenomas (3 or more at baseline), or those with the following histologic characteristics: villous or tubulovillous features, high-grade dysplasia, or carcinoma-in situ

Among 86 obese patients, 23 patients had recurrent adenomas at the end-of-study, including 6 recurrences among 43 patients (14 %) in the DFMO + sulindac group, and 17 recurrences among 43 patients (40 %) in the placebo group. The risk ratio of adenoma recurrence after treatment (compared to placebo, as a referent group) among obese patients was 0.32, 95 % confidence interval, CI = 0.15–0.71 (Table 2). Among the 181 non-obese patients, 49 patients had recurrent adenomas at the end-of-study, including 11 recurrences among 95 patients (12 %) in the DFMO + sulindac group, and 38 recurrences among 86 patients (44 %) in the placebo group. Among non-obese patients, the risk ratio of adenoma recurrence after treatment (compared to placebo, as a referent group) was 0.27, with 95 % CI = 0.15–0.49 (Table 2). In the full regression model including all 267 subjects, with adjustment for treatment group, obesity, age, aspirin use, and a term representing the interaction of obesity and treatment, no significant interaction was noted between treatment and obesity with regard to adenoma recurrence (p = 0.91). Main effects for obesity were not significant in the full risk models when analyzed as a dichotomous variable (obese vs. non-obese): RR = 1.20, 95 % CI 0.72–2.02; p = 0.49, or as a continuous variable (BMI): RR = 1.01, 95 % CI 0.98–1.05; p = 0.45. Further analyses based on risk of multiple or advanced adenomas were not performed due to a low number of events in the treatment group.
Table 2

Colorectal adenoma recurrence risk* after treatment with DFMO + sulindac versus placebo, by obesity status at baseline

 

Non-obese patients (n = 181)

Obese patients (n = 86)

n

Risk ratio (95 % confidence interval)

p

n

Risk ratio (95 % confidence interval)

p

Recurrent adenoma events

Any adenoma

49

0.27 (0.15–0.49)

<0.0001

23

0.32 (0.15–0.71)

0.005

Risk ratios indicate the effect of DFMO + sulindac compared with placebo (as a referent value) on recurrent colorectal adenomas

* Relative risk estimation by log-binomial regression. Likelihood ratio test p values are reported. Risk ratios indicate risk of metachronous adenoma after treatment with DFMO + sulindac versus placebo (referent group). All risk ratios are adjusted for aspirin intake

Discussion

Here, we report that obesity does not modify the CRA risk reduction previously ascribed to DFMO + sulindac versus placebo. We observed a 68 % reduction in recurrent CRA among obese patients (vs. 73 % reduction among non-obese patients) after prolonged administration of DFMO + sulindac compared with placebo. Obesity itself was not found to be associated with recurrent CRAs, a finding congruent with some—but not all previous reports [4, 13, 14]. Obesity was associated with several baseline adenoma characteristics that are risk factors for advanced adenoma recurrence; however, the trial was not designed to prospectively stratify patients by obese status in the randomization process. In contrast to results from mouse model experiments noting associations between obesity and polyamine levels [10], we did not observe any differences in rectal tissue polyamine levels among trial participants based on obesity status at baseline (Table 1).

Inconsistencies in the literature regarding associations between obesity and risk of CRA or CRC may be partly related to obesity definitions. While many studies have utilized BMI as an indicator of obesity, other measures of obesity are studied (e.g., waist circumference, waist-to-hip ratio, visceral adipose tissue). Abdominal obesity has been shown to be linked to insulin resistance and hyperinsulinemia [15], which has been suggested to underlie the association of obesity and CRA. In vitro studies have shown that insulin promotes cell growth in colonic mucosa and in colon carcinoma cells [16]. Epidemiological data indicate that metabolic syndrome, a cluster of metabolic abnormalities including insulin resistance and central obesity, as well as insulin-dependent Type II diabetes, are biological risk factors for the development of CRAs and CRCs [17]. Insulin levels and insulin-like growth factor-I are positively associated with CRA incidence, especially advanced adenomas. Interestingly, the same study found no association between visceral adipose tissue and BMI and adenoma risk [13]. Therefore, obesity may be acting as a surrogate risk factor not only for hyperinsulinemia, but also for other potential underlying factors such as low physical activity or high-risk dietary patterns [18]. As these factors typically do not exist in isolation, it remains difficult to determine to what degree each of these factors plays a role in colorectal adenoma and cancer risk.

A recent Japanese study investigated how the adipokines mediate associations between obesity and CRC [19]. An inverse association between adiponectin level and CRA was found, whereas a positive association of leptin was noted. Adiponectin may exert anticarcinogenic effects on the large intestine by interfering with leptin, whereas leptin could conversely exert carcinogenic effects under conditions of lower adiponectin levels. Since adipokines play an important role in insulin resistance [20], future studies on the interactions between adipokines and the insulin pathway may better elucidate underlying mechanisms. A National Cancer Institute-sponsored multi-institutional phase IIa clinical biomarker trial investigating adipokines and other relevant biomarkers pre- and post-metformin treatment in obese CRA patients is currently ongoing at the University of California Irvine, with results anticipated in 2013 [21].

Several limitations of this study must be acknowledged. Our analysis was performed using data from the controlled setting of a phase III trial with a relatively small sample size. The recurrence analysis was limited by the overwhelming effect of treatment in approximately half of the study population (i.e., some of the effects of obesity, if present, may have been minimized). Additionally, we were not able to test other measures of obesity (e.g., central obesity or percentage body fat), which may have resulted in different outcomes, and did not account for other relevant lifestyle or hormonal factors. It is possible that differences in drug metabolism may occur based on the volume of distribution (which is increased in patients with large amounts of adipose tissue) or under-dosing due to a particular fixed-dose regimen utilized here. For example, in oncology, drug dosing of obese patients has been identified as a potential factor for the observed poor outcomes among obese cancer patients. In obese cancer patients, it is believed that fixed drug dosing or dose “capping” (i.e., limiting the body surface area to a pre-specified maximum number) may result in inadequate drug delivery [22]. It is important to note that the tissue polyamine contents evaluated here refer to steady-state levels of specifically rectal mucosal polyamine contents. Differences in adipose tissue polyamine contents were not addressed in our study, which represents a limitation of the analysis. Additionally, we did not examine total polyamine flux—which may be important in understanding polyamine effects on metabolism.

Our analysis suggests that obesity does not substantially modify CRA risk reduction after treatment with DFMO + sulindac compared with placebo. This has implications for therapeutic prevention of CRAs, since a key goal of cancer prevention clinical trials is to refine the risk:benefit, and risk:risk profile of chemopreventive agents. The large risk reduction afforded to CRA patients receiving DFMO + sulindac as compared to placebo in the parent trial appears to occur regardless of whether or not patients are obese. Potential benefits of lifestyle modifications on colorectal carcinogenesis in general (including control of obesity, increasing physical activity, and specific dietary modifications) are clearly relevant and beyond this scope of this manuscript.

Participating institutions and investigators

Chao Family Comprehensive Cancer Center, University of California Irvine, CA: Frank L. Meyskens Jr, MD (Principal Investigator); Gregory Albers, MD; Sharon Fujikawa-Brooks, PhD; Philip M. Carpenter, MD; Daniel L. Gillen, PhD; Christine E. McLaren, PhD; Daniel Pelot, MD. Arizona Cancer Center, University of Arizona, AZ: Eugene W. Gerner, PhD; Steven Goldschmid, MD; Peter Lance, MD. Denver Department of Veteran Affairs Medical Center and University of Colorado: Dennis J. Ahnen, MD. Department of Veterans Affairs Long Beach Healthcare System, CA: Jayashri Kidao, MD. Kaiser Permanente, Sacramento, CA: Michael J. Lawson, MD. Loma Linda University, CA: John McCracken, MD. Department of Veterans Affairs Loma Linda Healthcare System, CA: Ronald Griffen, MD. University of Michigan, Ann Arbor, CA: D. Kim Turgeon, MD. University of Kansas, Kansas City, CA: Curt H. Hagedorn, MD.

Acknowledgments

This work was supported in part by National Cancer Institute contract N01-CN75019 (F.L.M. and C.E.M.) and grants CA59024 (F.L.M.), CA88078 (F.L.M. and C.E.M.), P30 CA62230 (F.L.M.), CA23074 (E.W.G.), and CA95060 (E.W.G.). B.S.L. was supported in part by Pfizer Oncology Clinical Fellowship in Translational Cancer Prevention. All authors contributed to the writing and final approval of the article.

Conflict of interest

F.L.M. and E.W.G. have ownership interest in Cancer Prevention Pharmaceuticals, LLC. The funders did not have any involvement in the design of the study; the collection, analysis, and interpretation of the data; the writing of the article; or the decision to submit the article for publication.

Open Access

This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Copyright information

© The Author(s) 2012